Clinical trial / 2006
Creatine supplementation did not increase urinary excretion of the carcinogen N-nitrososarcosine
A double-blind, placebo-controlled study in healthy humans evaluated the urinary excretion of the carcinogen N-nitrososarcosine during creatine supplementation. Participants took a high dose of creatine (20 g/d) for one week followed by a low dose (5 g/d) for 20 weeks. Oral creatine ingestion did not systematically elevate urinary excretion of N-nitrososarcosine.
- Study type
- Double-blind, placebo-controlled trial
- Who was studied
- Healthy human volunteers
- What was measured
- Urinary N-nitrososarcosine excretion
THE PAPER
Oral creatine supplementation in humans does not elevate urinary excretion of the carcinogen N-nitrososarcosine.
Derave W, Vanden Eede E, Hespel P, Carmella SG, Hecht SS. Nutrition, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.